Why Eli Lilly (LLY) Stock Is Up Today

2026-10-22

Investivoq PriceTracker

Eli Lilly and Company (LLY) is up 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is fresh positive pipeline news from Lilly, highlighted by new Phase 3 data for Omvoh in pediatric ulcerative colitis that met the study’s primary endpoint and supported a potential regulatory expansion. Investors also appear to be positioning ahead of Lilly’s October 29, 2026 third-quarter earnings report, with recent analyst target increases adding to the bullish tone. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-clinical?utm_source=openai))

Details:

Lilly announced on October 19 that Omvoh delivered positive one-year Phase 3 results in patients ages 6 to 17 with moderately to severely active ulcerative colitis. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-clinical?utm_source=openai))

In that study, 81% of patients achieved clinical response at Week 12, and 50% of responders reached clinical remission at Week 52, which met the primary endpoint. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-clinical?utm_source=openai))

Lilly said it plans to submit the data to global regulators for a possible pediatric label expansion, giving the update potential commercial significance beyond the immediate trial result. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-clinical?utm_source=openai))

Near-term sentiment may also be benefiting from rising expectations into Lilly’s October 29 earnings release and from higher analyst price targets issued this week. This could be because investors are looking for another strong update on Lilly’s growth outlook. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-third-quarter-2026?utm_source=openai))

Sources:

Eli Lilly and Company, Yahoo Finance, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LLY Insider Trading Activity

$LLY insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$LLY Hedge Fund Activity

We have seen 2,509 institutional investors add shares of $LLY stock to their portfolio, and 1,631 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 12,598,524 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,111,047,641
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 6,001,955 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,198,924,885
CAPITAL RESEARCH GLOBAL INVESTORS removed 3,759,507 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $4,509,265,481
WELLINGTON MANAGEMENT GROUP LLP removed 2,428,108 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $2,912,345,578
FMR LLC added 2,121,444 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $2,544,523,576
SG AMERICAS SECURITIES, LLC added 1,331,427 shares (+204.1%) to their portfolio in Q2 2026, for an estimated $1,596,953,486
GOLDMAN SACHS GROUP INC added 1,312,095 shares (+20.7%) to their portfolio in Q2 2026, for an estimated $1,573,766,105

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$LLY Congressional Stock Trading

Members of Congress have traded $LLY stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
REPRESENTATIVE MICHAEL A. RULLI sold up to $15,000 on 07/01.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $100,000 on 06/10.

To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

$LLY Price Targets

Multiple analysts have issued price targets for $LLY recently. We have seen 11 analysts offer price targets for $LLY in the last 6 months, with a median target of $1350.0.

Here are some recent targets:

Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.